<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13287">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01921907</url>
  </required_header>
  <id_info>
    <org_study_id>AD17137</org_study_id>
    <nct_id>NCT01921907</nct_id>
  </id_info>
  <brief_title>Evaluation of a Topical Treatment for Actinic Keratosis</brief_title>
  <official_title>Phase 2 Double-blind, Randomized, Placebo-controlled, Parallel Group, Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assuta Hospital Systems</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assuta Hospital Systems</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      A topical treatment applied twice daily for 4 weeks to induce disappearance   of facial
      actinic keratosis (AK). First 4 weeks treatment  (visit 1, 2 and 3 at 0,2 an 4 weeks)
      treated as a double blind parallel study. From weeks 4 to 7 (visit 3 to visit 4) all
      patients to be treated by the active component.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Complete Clearance (100% of AK lesions) from baseline (Visit 1) to Visits 3 and 4.  Complete Clearance (100% of AK lesions) from baseline (Visit 1) to Visits 3 and 4.</measure>
    <time_frame>baseline to Week 7</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial Clearance (75% of AK lesions) from baseline (Visit 1) to Visits 3 and 4.</measure>
    <time_frame>baseline to Week 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in lesion size</measure>
    <time_frame>baseline to Week 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Investigator Global Assessment</measure>
    <time_frame>baseline to Week 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in lesion number</measure>
    <time_frame>baseline to Week 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Global Assessment</measure>
    <time_frame>baseline to Week 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Actinic Keratosis of Face and Scalp</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>topical treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AD17137 topical treatment</intervention_name>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females 30 to 90 years old, inclusive, in good general health

          -  Clinical diagnosis of Actinic Keratosis

          -  At least 2 clinically diagnosed, 3-15 mm AK lesions on face or scalp

          -  Patient is competent to understand and sign a consent form, and is willing and able
             to follow study procedures and attend all visits

          -  Female patients of childbearing potential must have a negative urine pregnancy test
             prior to receiving study medication

          -  Sexually active women of childbearing potential participating in the study must use a
             medically acceptable form of contraception

          -  Pharmacologic methods of contraception should be stable for 1 month prior to Visit 1
             and be maintained at same dose during the study

        Exclusion Criteria:

          -  Patients who had been treated with: 5-FU, diclofenac, retinoids, ingenol mebutate or
             imiquimod within 4 weeks of study, immunomodulators, or interferon/interferon
             inducers or systemic immunosuppressants within 8 weeks of study, cryodestruction,
             curettage, photodynamic therapy, surgical excision on the treatment area within 4
             weeks of study, systemic cancer therapy, UVA therapy, UVB therapy, laser abrasion,
             dermabrasion

          -  History of hereditary angio-edema, Epilepsy or Parkinson's Disease

          -  Erythroderma or history of immunodeficiency disorders

          -  Pregnancy, lactation or patient who is not practicing effective contraception

          -  History of alcohol and drug abuse within 5 years of screening

          -  Known hypersensitivity or previous allergic reaction to any of the components of the
             study medication

          -  Having a member of the same household in the trial

          -  Patient has participated in an investigational clinical, surgical, drug or device
             study within the past 30 days

          -  Patients who in the opinion of the investigator should not be included in the study
             for any reason, including inability to follow procedures
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Avi Dascalu, M.D., Ph.D.</last_name>
    <phone>+97236099005</phone>
    <email>dasc01@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maccabi Health Clinic</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6495301</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>August 12, 2013</lastchanged_date>
  <firstreceived_date>July 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic keratosis</keyword>
  <keyword>topical</keyword>
  <keyword>dermatology</keyword>
  <keyword>treatment</keyword>
  <keyword>clinical study</keyword>
  <keyword>double blinded</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
